Monthly Archives: February 2012

Diverse approach to cancer research need of the hour, stresses professor Profoundly different approaches are needed for cancer research, the Qatar International Conference on Stem Cell Science and Policy 2012, has been told by an expert in cancer stem cell (CSC) biology. Professor Irving Weissman, director, Stanford Institute for Stem Cell Biology and Regenerative Medicine, Stanford University, was delivering a keynote address on ‘Normal and neoplastic stem cells’ yesterday. “Self-renewal is the principal property that distinguishes stem cells from their daughter cells,” he said while explaining that when stem cells divide they give rise to stem cells (by self-renewal) and progenitors (by differentiation). The balance between self-renewal and differentiation is what generates, and then maintains, tissues enabling them to respond to injury or other stressors. Studies identifying hematopoietic stem cells (HSC) - which form blood and immune cells - and progenitors, have made hematopoiesis one of the best systems for studying the molecular changes in cell fate decision-making and creation of cancer. Further, it serves as a paradigm for finding preclinical and clinical platforms for tissue and organ replacement and regeneration. Stem cell isolation and transplantation is the basis for regenerative medicine. Self-renewal is dangerous and therefore strictly regulated. Poorly … Continue reading →

28-02-2012 12:18 FREE STEM CELL BOOK! myjdimlm.com PUBLIC SERVICE VIDEO Home of JDI Multi Vitamin-Minerals with Stem Cell Nutrition Support Overcome the Aging Process. As we age, the body releases fewer and fewer adult stem cells which are the body's rebuilding tools. Stem cell nutrition helps overcome the aging process by promoting the release of additional adult stem cells in the body. This book contains over 70 different stories from doctors, everyday people, and even about how stem cell nutrition helps animals. Get this book FREE with your first purchase or when you become an active auto-ship member. Join us TODAY and start the Journey that will set you FREE!!! http Enhance your Stem Cells with JDI MultiVitamin with Stem Cell Nutrition Support utilizing... Vita-Stim™ Stem Cell Nutrition Vita-Stim is an all-natural patented supplement that helps to increase the release of adult stem cells or what are also known as progenitor cells noted below. It is not to be confused with any other product that has less than 750 mg. of active ingredient per capsule and could consist of merely fruit extracts and/or simply Aphanizomenon flos-aquae (AFA) extracts. See original here: Stem Cell Therapy Book ~ Enhance Your Stem Cells … Continue reading →

(RTTNews.com) - Baxter International Inc. (BAX) said it has initiated a phase III pivotal clinical trial to evaluate the efficacy and safety of adult autologous CD34+ stem cells to increase exercise capacity in patients with chronic myocardial ischemia. Chronic myocardial ischemia is one of the most severe forms of coronary artery disease, causing significant long-term damage to the heart muscle and disability to the patient. The company said that the trial will enroll approximately 450 patients across 50 clinical sites in the United States, who will be randomized to one of three arms, namely treatment with their own autologous CD34+ stem cells, treatment with placebo (control), or unblinded standard of care. The primary objective is to evaluate the efficacy of treatment with CD34+ stem cells to improve the functional capacity of patients with chronic myocardial ischemia, as measured by a change in total exercise capacity at 12 months following treatment. Efficacy will be measured by a change in total exercise capacity during the first year following treatment and safety data will be collected for two years. The company noted that the trial is being initiated based on the phase II data, which indicated that injections of patients' own CD34+ stem … Continue reading →

SUNRISE, Fla., Feb. 28, 2012 (GLOBE NEWSWIRE) -- Bioheart, Inc. (BHRT.OB) announced that the company will conduct the ANGEL trial using adipose (fat) derived stem cell technology or LipiCell(TM) at the University of Miami Miller School of Medicine. Bioheart recently applied to the FDA to begin trials using adipose derived stem cells in patients with chronic ischemic cardiomyopathy. "Dr. Joshua Hare and the University of Miami are world leaders in the field of stem cell research," said Mike Tomas, President and CEO of Bioheart. "We look forward to working with these acclaimed experts and bringing the LipiCell(TM) technology to patients in the U.S." The clinical protocol of the ANGEL trial is designed to assess the safety and cardiovascular effects of intramyocardial implantation of autologous adipose derived stem cells (LipiCell(TM)) in patients with chronic ischemic cardiomyopathy. Joshua Hare, MD, Director of the Interdisciplinary Stem Cell Institute at the University of Miami Miller School of Medicine is the principle investigator of the clinical program. The Interdisciplinary Stem Cell Institute was established to capitalize on pioneering work in the use of adult stem cells for the repair of malfunctioning human organs. The goal of the Institute is to find new treatments for heart … Continue reading →

Experts discuss stem cell banking ethics, policies By Noimot Olayiwola Staff Reporter Umbilical cord blood banking and transplantation, issues of ethics and policy as well as regulations governing stem cell banking were some of the high points of discussion during a session on ‘Stem Cell Banking’ at the Qatar International Conference on Stem Cells Science and Policy, underway at the Qatar National Convention Centre. Sharing the Saudi Arabia experience on umbilical cord blood transplantation during a presentation, King Faisal Specialist Hospital and Research Centre’s blood bank (transfusion & donor services) director and of the Stem Cell Cord Blood Bank at the department of pathology and laboratory medicine, Dr Hind al-Humaidan, noted that the transplantation of allogeneic (taken from different individuals of the same species) bone marrow has been successfully used in the treatment of high risk or recurrent hematologic malignancies, bone marrow failure syndromes, selected hereditary immunodeficiency states and metabolic disorders. “Early in the history of bone marrow transplantation, it was clear that access to a suitable donor was a major obstacle severely limiting the use of this potentially curative treatment modality. Although using an HLA (human leukocyte antigen) sibling donor is the best choice for transplantation, not all patients … Continue reading →

DEERFIELD, Ill.--(BUSINESS WIRE)-- Baxter International Inc. (NYSE:BAX - News) announced today that it has initiated a phase III pivotal clinical trial to evaluate the efficacy and safety of adult autologous (an individual’s own) CD34+ stem cells to increase exercise capacity in patients with chronic myocardial ischemia (CMI). Chronic myocardial ischemia (CMI) is one of the most severe forms of coronary artery disease, causing significant long-term damage to the heart muscle and disability to the patient. It is often diagnosed based on symptoms of severe, refractory angina, which is severe chest discomfort that does not respond to conventional medical management or surgical interventions. “The prospect of using a person’s own adult stem cells to restore and repair blood flow in CMI is a very exciting concept based on a biological regenerative approach,” said Norbert Riedel, Ph.D., Baxter’s chief science and innovation officer. “The goals of this phase III trial are aligned with Baxter’s overall mission to develop life-saving and life-sustaining therapies and it will help us determine if the therapy can make a meaningful difference for CMI patients.” The trial will enroll approximately 450 patients across 50 clinical sites in the United States, who will be randomized to one of three … Continue reading →

SAN DIEGO, CA and PORTLAND, OR--(Marketwire -02/28/12)- Medistem Inc. (Pinksheets: MEDS.PK - News) announced today its Annual "Evening with Medistem" Event will take place in Portland, Oregon on March 7th, 2012. The event is being hosted by Vladimir Zaharchook, Vice Chairman at Medistem, Inc., and will feature stem cell luminaries and pioneers working with Medistem including Dr. Amit Patel, Director of Regenerative Medicine at University of Utah and the first person to administer stem cells into patients with heart failure, Dr. Michael Murphy, Vascular Surgeon at Indiana University and Principal Investigator for Medistem's FDA clinical trial in patients with risk of amputation, and Dr. Alan Lewis, former CEO of the Juvenile Diabetes Research Foundation, advisory board member of Medistem. In 2007 Medistem discovered an entirely new type of stem cell, the Endometrial Regenerative Cell (ERC). This cell has proven it is a "universal donor" and can be used to treat many more conditions compared to other types of stem cells. The company received FDA clearance to begin clinical trials in September of 2011 for critical limb ischemia, a condition that is associated with amputation. Medistem is also running a Phase II clinical trial for heart failure using the new stem … Continue reading →